A new study published in BMJ Open has found that GLP-1 receptor agonists - the class of drugs that includes semaglutide and tirzepatide - are associated with a 26% reduction in alcohol-related hospital admissions among adults with alcohol use disorder.
This is one of the largest studies to date examining the relationship between GLP-1 drugs and addiction outcomes, and it adds to a growing body of evidence suggesting these compounds may have effects that extend well beyond their original purpose.
The Study
The research was a multi-target trial emulation study published in BMJ Open on 21 July 2026. It was conducted by researchers from Truveta, Johns Hopkins Bloomberg School of Public Health, Duke University, Providence, and collaborating institutions.
The study used a large real-world dataset to compare alcohol-related hospitalisation rates among adults with alcohol use disorder who were prescribed GLP-1 receptor agonists versus those prescribed other diabetes medications. The analysis found that GLP-1 drugs were associated with a 26% lower risk of alcohol-related hospital admission.
This wasn’t a randomised controlled trial - it was an observational study using real-world data. That’s an important distinction. Observational studies can show associations but can’t prove causation. However, the size of the dataset and the rigorous statistical methods used (multi-target trial emulation) give the findings more weight than a typical retrospective analysis.
Why This Matters
The idea that GLP-1 drugs might affect addiction isn’t new. Anecdotal reports have been circulating for years from people taking semaglutide or tirzepatide who noticed reduced cravings for alcohol, nicotine, and other substances. Social media forums are full of personal accounts from people who say their relationship with alcohol changed dramatically after starting GLP-1 medications.
What’s new is the scale and rigour of the evidence. Previous studies have been smaller, often limited to specific populations, or relied on self-reported data. This BMJ Open study used hospital admission records - hard endpoints that are difficult to misreport - across a large, diverse population.
The findings align with a broader trend in GLP-1 research. These drugs were originally developed for type 2 diabetes, then found to be effective for obesity, then for cardiovascular risk reduction, and now potentially for addiction. The mechanism isn’t fully understood, but researchers believe GLP-1 receptors in the brain’s reward pathways may play a role.
The Mechanism Question
GLP-1 receptors are found not just in the pancreas and gut, but throughout the brain - including in areas associated with reward, motivation, and impulse control. The nucleus accumbens, ventral tegmental area, and prefrontical cortex all express GLP-1 receptors.
Animal studies have shown that GLP-1 receptor agonists can reduce alcohol intake, decrease motivation to seek alcohol, and reduce the rewarding effects of alcohol. These preclinical findings provide a plausible biological mechanism for the clinical observations.
However, translating animal findings to human outcomes is never straightforward. The brain’s reward circuitry is complex, and the doses used in animal studies don’t always correspond to human therapeutic doses. The BMJ Open study provides important real-world evidence that the preclinical findings may hold in humans, but the mechanism still needs more research.
What the Research Says
This study joins a growing list of research examining GLP-1 drugs beyond their original indications:
- A 2025 study in JAMA Psychiatry found that semaglutide was associated with reduced alcohol-related diagnoses in a large US cohort
- Multiple observational studies have reported reduced nicotine cravings among GLP-1 users
- Preclinical research has explored GLP-1 agonists for cocaine, opioid, and stimulant use disorders
- A separate analysis presented at recent medical conferences found similar patterns of reduced substance use among GLP-1 users
The consistency of findings across different study designs, populations, and outcome measures is notable. While no single study is definitive, the pattern is becoming harder to dismiss as coincidence.
Important Caveats
There are several reasons to be cautious about these findings:
Observational design - Even with rigorous methods, observational studies can’t prove that GLP-1 drugs caused the reduction in hospitalisations. People prescribed GLP-1 drugs may differ from those prescribed other medications in ways that affect alcohol use.
Confounding factors - People who are prescribed GLP-1 drugs may be more engaged with healthcare, more motivated to change behaviours, or have different socioeconomic profiles than those on other diabetes medications.
Selection bias - The study population was limited to adults with alcohol use disorder who were also prescribed diabetes medications. This may not represent the broader population of people with alcohol use disorder.
No randomised trial yet - Several randomised controlled trials examining GLP-1 drugs for alcohol use disorder are underway, but results aren’t expected until 2027-2028. Until those results are available, the evidence remains suggestive rather than conclusive.
The Australian Context
For the Australian research community, this study is relevant for several reasons. Australia has one of the highest rates of alcohol consumption in the developed world, and alcohol-related harm is a significant public health burden. The National Drug Strategy Household Survey consistently finds that a substantial proportion of Australians exceed recommended drinking guidelines.
If GLP-1 drugs do reduce alcohol-related harm, the implications for public health policy would be significant. However, it’s important to note that no regulatory body - in Australia or elsewhere - has approved GLP-1 drugs for alcohol use disorder. These are early-stage findings that need confirmation in controlled trials before they can inform clinical practice.
The TGA has approved GLP-1 receptor agonists for type 2 diabetes and obesity, but not for any addiction-related indication. Any use for alcohol use disorder would be off-label and should only be considered under medical supervision.
What’s Next
Several clinical trials are underway examining GLP-1 drugs specifically for alcohol use disorder:
- A Phase 2 trial of semaglutide for alcohol use disorder at the National Institute on Drug Abuse (NIDA)
- Multiple university-led trials examining tirzepatide for alcohol and nicotine use disorders
- A European trial examining liraglutide for alcohol dependence
These trials will provide the randomised controlled data needed to determine whether GLP-1 drugs can be a viable treatment option for addiction. Results are expected in 2027-2028.
In the meantime, the BMJ Open study adds to the evidence that GLP-1 receptor agonists may have benefits that extend far beyond blood sugar control and weight management. The research community is watching closely.
Related Reading
For more on how GLP-1 drugs work, see our explainer on GLP-1 weight loss science. For the latest on the obesity drug landscape, check our coverage of the ADA 2026 conference.
Join the Grey Highway Telegram community to discuss this research with other Australian researchers.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.